Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9612 posts found.

jj_sign_on_wall

J&J stops Invokana trial early after success in kidney disease and type 2 diabetes

July 17, 2018 Manufacturing and Production, Research and Development J&J, JJ, Janssen, Johnson & Johnson, invokana, kidney disease, pharma, renal, type 2 diabetesm diabetes

Johnson & Johnson and research arm Janssen have taken the decision to terminate a Phase 3 trial evaluating the efficacy …
News
patient_graphic

Recruitment and retention: How can we do better?

July 16, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing clinical trials, feature, patient recruitment, patients, pharma

In pharma R&D, data is king, but consistent struggles with patient retention is undermining the integrity of clinical findings. Matt …
Feature
takeda_usa_pharmaceuticals_u

Takeda’s Ninlaro clears Phase 3 endpoint as maintenance therapy in multiple myeloma

July 12, 2018 Medical Communications, Research and Development Ninlaro, Takeda, multiple myeloma, pharma

After making headlines with its mammoth deal to acquire Shire earlier this year, Takeda has emerged with new Phase 3 …
News
top_10_image

Top Ten most popular articles on Pharmafile.com this week

July 12, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, Pfizer, Sanofi, Trump, top 10

In the week leading up to Donald Trump’s visit to the United Kingdom, the news has been dominated by the …
News
shutterstock_273326141

Otsuka snaps up Visterra in $430 million deal

July 12, 2018 Research and Development, Sales and Marketing Otsuka, Visterra, acquisition, pharma

Otsuka Pharmaceutical has announced it has reached a definitive, board-approved agreement with Visterra to acquire the latter company in an …
News

AbbVie and Janssen announce failure of cancer drug Imbruvica in Phase 3 trial

July 12, 2018 Research and Development AbbVie, Cancer, FDA, Janssen, approval

AbbVie and Janssen have announced that Imbruvica (ibrutinib) failed to achieve the primary endpoint in a late-stage study assessing its …
News
celgene_building

Celgene and Acceleron’s blood disorder drug smashes endpoints at Phase 3

July 11, 2018 Research and Development Acceleron, Celgene, beta-thalassemia, luspatercept, pharma

Celgene and Acceleron have lifted the curtain on new Phase 3 data for their erythroid maturation agent (EMA) luspatercept, confirming …
News
westminster-parliament-resized

UK Government announces £10m antimicrobial resistance research competition

July 11, 2018 Research and Development 10 million, antimicrobial, competition, government, resistance

The UK Government’s Department of Health and Social Care has announced the launch of a £10 million research competition aimed …
News
28246711066_52e38bc591_z

EMA survey identifies gaps in pharma industry’s preparedness for Brexit

July 11, 2018 Research and Development CAPS, EEA, EMA, brexit, preparedness

An EMA survey has identified gaps in the pharmaceutical industry’s preparedness for Brexit, finding that only 58% of market authorisation …
News

Wellcome Trust announces £250m fund for high risk ideas

July 11, 2018 Research and Development 250 million, Wellcome, britain, leap fund, pharma

The London-based biomedical research charity the Wellcome Trust, Britain’s wealthiest foundation, has announced the launch of a new £250 million …
News
shutterstock_254160583

Trump forces Pfizer to back down and delay price hikes until 2019

July 11, 2018 Research and Development, Sales and Marketing Alex Azar, Donald Trump, Ian Read, Pfizer, President trump, Trump, druig pricing, pharma

Trump bared his teeth, and it paid off. Following his call-out of Pfizer after the US pharma giant ignored the …
News
mario_saltarelli_cropped

Syntimmune appoints Pfizer, AbbVie veteran as new CMO

July 10, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, CMO, John Hopkins University, Pfizer, Syntimmune

The Boston-based clinical biotechnology company Syntimmune has appointed Dr Mario Saltarelli as its Chief Medical Officer. Dr Saltarelli will take …
Appointment

NICE calls to limit antibiotic use in COPD over antimicrobial resistance fears

July 10, 2018 Manufacturing and Production, Medical Communications, Research and Development COPD, NICE, antimicrobial resistance, chronic obstructive pulmonary disease, pharma

NICE have published a draft antimicrobial prescribing guide recommending that healthcare professionals should consider the risk of antimicrobial resistance when …
News

Eisai and Biogen’s Alzheimer’s drug slows progression in Phase 2 trials

July 9, 2018 Research and Development, Sales and Marketing

The Japan-based Eisai and Massachusetts-based Biogen have announced that experimental drug BAN2401 has demonstrated efficacy in slowing the progression of …
News
shutterstock_212035546

Extended use of breast cancer drug tamoxifen linked to increased endometrial cancer risk

July 9, 2018 Research and Development, Sales and Marketing Cancer, breast cancer, endometrial cancer, pharma, tamoxifen

New evidence published in the British Journal of Surgery has indicated a troubling link between long-term use of the breast …
News
The Gateway to Local Adoption Series

Latest content

Ofichem brings all brands under single trading name

April 23, 2026

Carvolix strengthens its Board of Directors, advisory board and governance structure

April 23, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

April 22, 2026

Incyclix Bio announces new additions to the Board

April 22, 2026

Remedy Plan Therapeutics Appoints Jotin Marango as CFO and CBO

April 21, 2026